Drug Discovery Informatics Market is expected to reach US$ 8.17 Billion by 2031

Global Drug Discovery Informatics Market Forecast to 2031: Key Insights

According to our latest study on "Global Drug Discovery Informatics Market – Global and Regional Share, Trend, and Growth Opportunity Analysis – by Workflow, Service, Solution, End User, and Geography," the market was valued at US$ 3.39 billion in 2024 and is expected to reach US$ 8.17 billion by 2031. The drug discovery informatics market size is estimated to register a CAGR of 13.7% during 2025–2031. The convergence of technological advancements, increasing research and development investments, and shifting industry practices is driving the growth of the drug discovery informatics market. Integration of artificial intelligence (AI) and machine learning (ML) is likely to bring new drug discovery informatics market trends in the coming years.

The increasing prevalence of chronic diseases all over the world is one of the main factors that greatly affect the drug discovery-informatics market. Different chronic diseases such as cancer, diabetes, cardiovascular diseases and neurodegenerative disorders are the main reasons for death and sickness globally and that have been the case for a long time. The rise in diseases is thus fueling the need for newer, effective and more targeted therapies. The Centers for Disease Control and Prevention state that, in 2024, a trend of increasing multichronic conditions in America was observed; 42% had two or more, and 12% were at least five. Pharmaceutical companies and research institutions must adopt informatics-based methods to make drug discovery process faster, make therapeutic outcomes better, and manage rising healthcare costs.

Drug Discovery Informatics Market

Comparatively, drug discovery informatics is the only option that can provide such facilities as handling and processing clinical and biological data on a massive scale related to chronic conditions. These techies not only enhance the abilities of scientists to delve deeper into convoluted patient data, but they also allow a part of the objects under study, such as biomarkers, and find the molecular pathways that are due to the progression of such diseases. Moreover, the use of real-world data analytics, which can involve electronic health records (EHRs), genomic sequences, and patient-reported outcomes, has made drug target identification and drug candidate optimization more accurate and efficient.

North America is still the leader in drug discovery informatics market worldwide. The main reasons for this are the investments that have been made in research and development and the technological innovations. The US government has set aside $48 billion for the National Institutes of Health for the fiscal year 2023, with a large part of the funding being allocated to computational biology and AI applications in drug development. This area is responsible for around 63% of the world& pharmaceutical research and development expenditures, making it an ideal place for the growth of bioinformatics. Some of the top academic institutions like MIT and Stanford are working with pharmaceutical companies to find new ways of using machine learning and over 300 Al drug discovery startups have come up in the last ten years. The FDA's evolving regulatory framework for digital health technologies further accelerates adoption. These factors contribute to North America's significant drug discovery informatics market share.

Advancements in Personalized Medicine to Drive Global Drug Discovery Informatics Market Growth

The revolutions in custom-made medication have changed the drug discovery informatics market in an enormous way, the main reason being the need for such instrumentation and platforms which could assimilate and properly interpret the biological data from different sources to give a clear picture of patient-specific therapies. Personalized medicine is an approach that focuses on the genetic, environmental, and lifestyle factors of an individual to come up with the most appropriate drug at the right time. Compared to traditional "one-size-fits-all" therapies, this method is more efficient, safer, and also saves on healthcare resources.

In such a setting, the need for drug discovery informatics solutions to handle and manage diverse data sets from genomic sequencing, proteomics, metabolomics, and patient health records becomes imperative is unarguable. Identifying the patient population groups who will benefit the most from the newly discovered drug candidates is made easier through informatics platforms, thus, leading to the development of targeted therapy. The use of these tools in biomarker discovery, the development of companion diagnostic, and predictive modeling has become very prominent in practice to advance clinical treatment strategies.

Personalized medicine is a major factor for the spending of big amounts on the informatics infrastructure by pharmaceutical and biotech companies. They are eager to make use of this change of model. Those companies that manage to tailor the drug discovery to the requirements of the patient will be able to set themselves apart by producing drugs that have higher chances of success, that can be sold at a premium price, and that respond to previously unmet medical needs. Besides that, the support of the regulatory agencies is becoming stronger. They back personalized medicine initiatives through provision of guidance frameworks and simplified approval procedures, thus creating a favorable environment for innovation. Therefore, the progress in personalized medicine is the main driver of the drug discovery informatics market.

.

Global Drug Discovery Informatics Market: Segmental Overview

By workflow, the market is bifurcated into discovery informatics and drug development. The discovery informatics segment held a larger drug discovery informatics market share in 2024. Discovery Informatics division from the drug discovery informatics market is leading changes by the usage of data-centric methodologies to the drug formulation and delivery systems. This part delves into the use of computational tools, AI, and predictive analytics to facilitate the designing of the novel drug delivery systems, for instance, nanoparticles, liposomes, and targeted delivery platforms, which are the delivery systems intended to improve bioavailability, the stability of the drugs, and patient compliance. Indeed, as pharmaceutical firms progressively are looking to raise therapeutic efficiency, at the same time, bringing down the side-effects, discovery informatics only can do the job by simulating the drug-excipient interactions, forecasting the release profiles, and mimicking biological reactions in silico, thus, choosing the experimental stages. In this way, the experimental stages, which are usually done by trial and error, will be the last ones; therefore, the development cycles will be shortened, and finally, the cost of research and development will be slowed down. The main drivers of the market are, among others, the increasing need for precision medicine, the introduction of complex biologics that require new delivery solutions, and the progress in material science. Besides, the informatics solutions by combining historical data with real-time analytics can serve the purposes of regulatory compliance and formulation optimization.

Global Drug Discovery Informatics Market Analysis: Competitive Landscape and Key Developments

The global drug discovery informatics market report emphasizes the key factors driving the market and the prominent players' developments. 

Jubilant Pharma Limited.; Certera.; Thermo Fisher Scientific Inc.; Dassault Systemes SE; Revvity Inc.; Selvita.; Eurofins Scientific SE.; Collaborative Drug Discovery, Inc.; and Charles River Laboratories International Inc are among the prominent players profiled in the global drug discovery informatics market report. The market players focus on new product launches, expansion and diversification, and acquisition strategies, which allow them to access prevailing business opportunities.

• In February 2025, Jubilant Biosys Innovative Research Services Pte Limited, Singapore (JBIRSPL), a subsidiary of Jubilant Biosys Limited, a wholly-owned subsidiary of Jubilant Pharmova Limited, signed the final transaction agreements with Pierre Fabre SA, and its affiliate entities ("PF"), for JBIRSPL to take over 80% of the share capital of JASMIN [a new company established by PF in France, as a Société par Actions Simplifiée (SAS)], with the rest 20% owned by PF.
• In October 2024, Jubilant Biosys Innovative Research Services Pte Limited, Singapore (‘JBIRSPL’), a subsidiary of Jubilant Biosys Limited, a wholly owned subsidiary of Jubilant Pharmova Limited and Pierre Fabre SA entered a strategic partnership. Pursuant to this, JBIRSPL would acquire 80% equity capital in Jasmin (new company incorporated in France, as a Société par Aceons Simplifiée (SAS), 100% owned by Pierre Fabre). Jasmin shall acquire Pierre Fabre’s R&D Centre (Including R&D Site and R&D activities) at Saint Julien, France, upon closing of the transaction.

Contact Us

Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com